Yesterday I watched what I considered to be an historic FDA advisory committee meeting reviewing data supporting the approval of Entasis-Innoviva’s drug sulbactam-durlobactam (Sul-Duro) in the treatment of hospital acquired pneumonia caused by highly resistant strains of Acinetobacter.